Belgium· BE-AMP-SAM662372-00
Runrapiq 300 mg
A landiolol product containing landiolol hydrochloride, registered in Belgium by Orpha-Devel Handels und Vertriebs. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Landiolol is registered in 15 of 19 countries.
Countries holding a registration under ATC C07AB14 (landiolol), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Landiolol · ATC C07AB14
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Landiolol Hydrochloride
- Manufacturer
- Orpha-Devel Handels und Vertriebs
- Country
- Belgium (BE)
- ATC code
- C07AB14
- ATC class
- Landiolol
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb4996534
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Landiolol in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRAPIBLOCAmomed Pharma GmbH, Vídeň
- SpainRAPIBLOC 300 MG POLVO PARA SOLUCION PARA PERFUSIONOrpha-Devel Handels Und Vertriebs Gmbh
- SwitzerlandRapibloc 300 mg, Pulver zur Herstellung einer InfusionslösungOrPha Swiss GmbH
- IrelandRapibloc 300 mg powder for solution for infusionOrpha-Devel Handels und Vertriebs GmbH
- NorwayRaplocAmomed Pharma GmbH
- PolandRunrapiqAmomed Pharma GmbH
- United KingdomRapibloc 300mg powder for solution for infusion vialsAOP Orphan Ltd
- Japanランジオロール塩酸塩富士製薬工業
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Rapibloc
- Bulgaria · Рапиблок
- Cyprus · Rapibloc
- Czechia · Rapibloc
- Germany · Rapibloc
- Denmark · Rapibloc
- Estonia · Raploc
- Spain · Rapibloc
- Finland · Rapibloc
- France · Rapibloc
- Greece · Rapibloc
- Croatia · Rapibloc
- Hungary · Rapibloc
- Ireland · Rapibloc
- Italy · Landiobloc
- Lithuania · Raploc
- Latvia · Raploc
- Netherlands · Landiolol Hydrochloride Orpha-Devel, Rapibloc
- Norway · Raploc
- Poland · Runrapiq
- Portugal · Rapibloc
- Romania · Rapibloc
- Sweden · Rapibloc
- Slovenia · Rapibloc
- Slovakia · Rapibloc
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af703837-3190-4a99-8a94-014ee9d29e61 GET /v1/drugs/af703837-3190-4a99-8a94-014ee9d29e61?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Runrapiq 300 mg",
"name_fr": "Runrapiq 300 mg",
"name_nl": "Runrapiq 300 mg",
"amp_code": "SAM662372-00",
"strengths": [
"300.0000",
"300.0000",
"280.0000",
"280.0000",
"300.0000",
"0.0000"
],
"pack_count": 1,
"substances": [
"Landiolol Hydrochloride",
"Landiolol",
"Mannitol",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Landiolol",
"authorisation_numbers": [
"BE662372"
]
}See everything about landiolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.